Brand Name
Filspari
Generic Name
Sparsentan
View Brand Information FDA approval date: February 17, 2023
Classification: Endothelin Receptor Antagonist
Form: Tablet
What is Filspari (Sparsentan)?
FILSPARI is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy who are at risk for disease progression. FILSPARI is an endothelin and angiotensin II receptor antagonist indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy who are at risk for disease progression ( 1, 1.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
A Multicenter, Open-label Single Arm Study to Evaluate the Safety and Efficacy of Sparsentan in Posttransplant Immunoglobulin A Nephropathy (IgAN) or Focal Segmental Glomerulosclerosis (FSGS) (SPARX)
Summary: To evaluate the safety and efficacy of sparsentan tablets for the treatment of patients with proteinuria after kidney transplantation with once-daily dosing for 36 weeks.
A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases
Summary: To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.